17 studies found for:    Gilead | hepatitis c | Phase 3
Show Display Options
Rank Status Study
1 Active, not recruiting Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: June 2012
Primary Completion: October 2014
2 Recruiting Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
Conditions: Hepatitis C Virus;   HIV
Interventions: Drug: LDV/SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: February 2014
Primary Completion: March 2015
3 Completed A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects
Conditions: Hepatitis C,;   Human Immunodeficiency Virus
Interventions: Drug: Sofosbuvir;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: July 2012
Primary Completion: November 2013
4 Active, not recruiting A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects
Conditions: Chronic Hepatitis C;   Human Immunodeficiency Virus
Interventions: Drug: Sofosbuvir;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: January 2013
Primary Completion: April 2014
5 Active, not recruiting Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naïve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection.
Condition: Hepatitis C Virus
Interventions: Drug: Sofosbuvir;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: March 2013
Primary Completion: May 2014
6 Active, not recruiting Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
Condition: Chronic Hepatitis C Virus
Interventions: Drug: SOF/LDV;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: September 2012
Primary Completion: October 2014
7 Completed Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
Condition: Chronic Hepatitis C Virus
Interventions: Drug: LDV/SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: May 2013
Primary Completion: November 2013
8 Completed Safety and Efficacy of GS-5885/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV
Condition: Chronic Hepatitis C Virus
Interventions: Drug: GS-5885/sofosbuvir;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: January 2013
Primary Completion: November 2013
9 Active, not recruiting Sofosbuvir+RBV for 16 or 24 Weeks and Sofosbuvir+PEG+RBV for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection
Condition: Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: September 2013
Primary Completion: December 2014
10 Active, not recruiting Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection.
Condition: Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: June 2013
Primary Completion: April 2014
11 Completed GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Condition: Hepatitis C
Interventions: Drug: GS-7977;   Drug: RBV;   Drug: Placebo to match GS-7977;   Drug: Placebo to match RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: September 2012
Primary Completion: October 2013
12 Completed
Has Results
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
Condition: Chronic Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Placebo to match SOF;   Drug: Placebo to match RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: March 2012
Primary Completion: November 2012
13 Completed Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: June 2012
Primary Completion: April 2013
14 Completed Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: June 2012
Primary Completion: May 2013
15 Active, not recruiting Phase 3 Study of Sofosbuvir and Ribavirin
Condition: Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: February 2013
Primary Completion: April 2014
16 Completed
Has Results
Phase 3 Study of Sofosbuvir and Ribavirin
Condition: Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: PEG;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: December 2011
Primary Completion: January 2013
17 Recruiting Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
Condition: Chronic HCV Infection
Interventions: Drug: Sofosbuvir;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: March 2014
Primary Completion: April 2015

Indicates status has not been verified in more than two years